Compare
Eton Pharmaceuticals, Inc. vs Arcturus Therapeutics Holdings Inc. vs Nurix Therapeutics, Inc. vs ARS Pharmaceuticals, Inc.
| Latest fiscal year | Eton Pharmaceuticals, Inc. ETON | Arcturus Therapeutics Holdings Inc. ARCT | Nurix Therapeutics, Inc. NRIX | ARS Pharmaceuticals, Inc. SPRY |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-11-30 | 2025-12-31 |
| Revenue | $79.95M | $82.03M | $83.98M | $84.28M |
| Revenue growth (YoY) | +104.9% | -46.1% | +54.0% | -5.5% |
| Gross margin | 53.5% | n/a | n/a | n/a |
| Operating margin | -1.1% | -93.0% | -340.2% | -212.9% |
| Net margin | -5.8% | -80.2% | -314.9% | -203.3% |
| Net income | -$4.60M | -$65.78M | -$264.46M | -$171.30M |
| EPS (Diluted) | n/a | -$2.40 | -$3.05 | -$1.74 |
| Operating cash flow | $10.52M | -$74.27M | -$249.47M | -$170.87M |
| Free cash flow | $10.19M | -$74.50M | -$263.47M | -$171.21M |
| Cash & equivalents | $25.94M | $230.91M | $246.96M | $41.32M |
| Total assets | $92.11M | $271.15M | $688.13M | $327.65M |
| Total liabilities | $65.96M | $57.16M | $149.39M | $213.39M |
| Shareholders' equity | $26.15M | $213.99M | $538.75M | $114.26M |
| Return on year-end equity | -17.6% | -30.7% | -49.1% | -149.9% |
| Shares outstanding | 27.05M | 28.41M | 101.81M | 99.29M |
Revenue, most recent five fiscal years
| Fiscal year | Eton Pharmaceuticals, Inc. | Arcturus Therapeutics Holdings Inc. | Nurix Therapeutics, Inc. | ARS Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $79.95M Ended 2025-12-31 | $82.03M Ended 2025-12-31 | $83.98M Ended 2025-11-30 | $84.28M Ended 2025-12-31 |
| 1 year earlier | $39.01M Ended 2024-12-31 | $152.31M Ended 2024-12-31 | $54.55M Ended 2024-11-30 | $89.15M Ended 2024-12-31 |
| 2 years earlier | $31.64M Ended 2023-12-31 | $166.80M Ended 2023-12-31 | $76.99M Ended 2023-11-30 | $30.0K Ended 2023-12-31 |
| 3 years earlier | $21.25M Ended 2022-12-31 | $206.00M Ended 2022-12-31 | $38.63M Ended 2022-11-30 | $1.32M Ended 2022-12-31 |
| 4 years earlier | $21.83M Ended 2021-12-31 | $12.36M Ended 2021-12-31 | $29.75M Ended 2021-11-30 | $5.51M Ended 2021-12-31 |